[Home](https://econdesousa.github.io){: .btn}
[Research Interests](https://econdesousa.github.io/ResearchInterests){: .btn}
[Publications](https://econdesousa.github.io/Publications){: .btn}
[Supervisions](https://econdesousa.github.io/Supervision){: .btn}
[External Links](https://econdesousa.github.io/Links){: .btn}
[Contacts](https://econdesousa.github.io/Contacts){: .btn}
[CV](assets/CurriculumVitaeECS.pdf){:.btn target="_blank" rel="noopener"}
[Short CV](assets/ShortCV.pdf){:.btn target="_blank" rel="noopener"}
<!-- [HEROHE](https://econdesousa.github.io/HEROHE){: .btn} -->


# HEROHE Grand-Challenge

### Assessing HER2 status in breast cancer without immunohistochemistry or in situ hybridization

<!-- 
[HEROHE](https://econdesousa.github.io/HEROHE_GC/index){: .btn}
[Rules](https://econdesousa.github.io/HEROHE_GC/Rules){: .btn}
[Dataset](https://econdesousa.github.io/HEROHE_GC/Dataset){: .btn}
[Results](https://econdesousa.github.io/HEROHE_GC/Results){: .btn}
-->

<center>
	<figure>
		<img src="https://econdesousa.github.io/assets/HEROHE_ECDP2020_alpha.jpg" style="width:80%">
	</figure>
</center>

Details can be found at [HEROHE Grand-Challenge web page](https://ecdp2020.grand-challenge.org/){: .btn target="_blank" rel="noopener"}

## Abstract
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. 
As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly 
classify breast cancer and define appropriate therapy, which depends on the evaluation of the expression of different 
biomarkers such as the transmembrane protein receptor HER2. This evaluation requires several steps, including special 
techniques such as immunohistochemistry or in situ hybridization to assess HER2 status. With the goal of reducing the 
number of steps and human bias in diagnosis, the HEROHE Challenge was organized, as a parallel event of the 16th European 
Congress on Digital Pathology, aiming to automate the assessment of the HER2 status based only on hematoxylin and eosin 
stained tissue sample of invasive breast cancer. Methods to assess HER2 status were presented by 21 teams worldwide and 
the results achieved by some of the proposed methods open potential perspectives to advance the state-of-the-art.


<center>
	<figure>
		<img src="https://econdesousa.github.io/assets/GraphicAbstract.jpg" style="width:100%">
	</figure>
</center>



[Home](https://econdesousa.github.io){: .btn}
[Research Interests](https://econdesousa.github.io/ResearchInterests){: .btn}
[Publications](https://econdesousa.github.io/Publications){: .btn}
[Supervisions](https://econdesousa.github.io/Supervision){: .btn}
[External Links](https://econdesousa.github.io/Links){: .btn}
[Contacts](https://econdesousa.github.io/Contacts){: .btn}
[CV](assets/CurriculumVitaeECS.pdf){:.btn target="_blank" rel="noopener"}
[Short CV](assets/ShortCV.pdf){:.btn target="_blank" rel="noopener"}
<!-- [HEROHE](https://econdesousa.github.io/HEROHE){: .btn} -->


<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-3JWYKYVYDZ"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-3JWYKYVYDZ');
</script>